TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (18 - 75) with a nasal swab confirmed SARS-CoV-2 infection; testing positive within 4 days of enrollment~2. Ability to read, understand and provide informed consent (no legally authorized representatives may consent on their behalf) and study assessments in English~3. Ability for subject to comply with the requirements of the study (must/will have a valid email address, internet connection and phone number)~4. Willingness to self limit medications and supplements and report what they are taking~5. Comfortable self-administering oral medication and nasal swab sampling~6. Willingness to permit a review of their medical history and to provide medical data from their electronic medical record for the period of enrollment (14 days) and until resolution of Covid-19 related events. Individuals who are not current Swedish patients will be asked to identify their provider of record and provide access to specific elements of their electronic health record.~7. Reside within twenty-five miles of one of the Swedish campuses: First Hill, Ballard, Edmonds, Issaquah, Cherry Hill.~Exclusion Criteria:~1. Reported history or evidence of impaired liver or kidney function: GFR \<30 or bilirubin \>2x ULT or INR \> 2x ULT in the absence of anticoagulants~2. Known hypersensitivity to zinc or resveratrol~3. Diagnosis of COVID-19 or SARS-CoV-2 infection \>4 days before enrollment~4. Preexisting severe pulmonary disease requiring supplemental oxygen~5. Clinically evident impairment of cognitive function, per physician discretion~6. Active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion.~7. Active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion.~8. Pregnant or lactating females.~9. Coumadin treatment that can not be halted during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Resveratrol and Zinc Picolinate combination therapy (Type: ACTIVE_COMPARATOR): Resveratrol and Zinc Picolinate combination therapy
- Resveratrol Placebo and Zinc Placebo combination therapy (Type: PLACEBO_COMPARATOR): Placebo Resveratrol and Placebo Zinc combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cemented application of components~* bilateral subjects randomized by knee~* patients with pre-existing contralateral knee surgery~* painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, or traumatic arthritis where one or more compartments are involved~* correction of varus, valgus, or posttraumatic deformity~* sufficient soft tissue surrounding the knee, including the Anterior Cruciate Ligament~Exclusion Criteria:~* cementless application of components~* BMI greater than or equal to 40~* use of Anterior Stabilized Bearings~* patients with severe pre-operative varus or valgus deformity greater than or equal to 15 degrees~* correction or revision of previous joint replacement procedure on index knee~* infection~* sepsis~* osteomyelitis~Relative exclusion criteria:~* uncooperative patient or patient with neurological disorders who is incapable of following directions~* osteoporosis~* metabolic disorders which may impair bone formation~* osteomalacia~* distant foci of infections which may spread to the implant site~* rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram~* vascular insufficiency, muscular atrophy, neuromuscular disease~* incomplete or deficient soft tissue surrounding the knee, including the anterior cruciate ligament

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vanguard XP Bicruciate Knee System (Type: EXPERIMENTAL): 153 patients receive Vanguard XP Bicruciate Knee System
- Vanguard CR Knee System (Type: ACTIVE_COMPARATOR): 153 patients receive Vanguard CR Knee System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial of the TriFit™ Web Knee Brace

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 21 years;~2. BMI \< 40;~3. Medial or lateral knee Osteoarthritis as clinical diagnosis \[Kellgren-Lawrence grades 1-3 Osteoarthritis\];~4. Persistent knee pain beyond current treatment;~5. No history of corticosteroid injection or viscosupplementation injections in the last 3 months;~6. Able to comply with study requirements;~7. Capable and willing of signing informed consent.~Exclusion Criteria:~1. Age \< 21 years;~2. History of diabetic neuropathy;~3. History of traumatic onset of knee pain;~4. Undergone surgery on either lower limb within 6 months;~5. Unable to comply with study requirements;~6. Had previously received corticosteroid injections or viscosupplementation injections in the affected knee within 3 months of study;~7. KL grade \>3

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A patient may be considered for study participation if all of the following apply:~1. Outpatient of either sex aged ≥ 16 years or older.~2. The patient has a confirmed diagnosis of IBD.~3. No plans to move \> 200 miles from Nashville in the subsequent 12 months.~4. The patient has read, understood and signed a written informed consent form. Permission of a minor participant will be obtained via a parent consent form.~Exclusion Criteria:~The patients will be excluded from the study if one or more of the following apply:~1. Unable to give consent.~2. Does not meet inclusion criteria above.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Joint Visits (Type: EXPERIMENTAL): Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
- Control (Type: NO_INTERVENTION): Transition patients in the control group will transfer care to adult GI provider in typical manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Hamstring Stretching and Neural Mobilization on Range of Motion and Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred to physical therapy for low back pain with limitations in hamstring range of motion on the painful side~Exclusion Criteria:~* Red flags

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- straight leg raise (Type: EXPERIMENTAL): stretch the muscle
- neural mobilization (Type: EXPERIMENTAL): stretch the nerve

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observation or Radical Treatment in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Diagnosed within 6 months prior to randomization~* Patient has been classified as favorable risk as defined by the following:~  * Clinical stage T1b, T1c, T2a, or T2b at the time of diagnosis~ * Clinical (diagnostic biopsy) Gleason score ≤ 6~ * PSA ≤ 10.0 ng/mL~* Physical examination, rectal examination, and transrectal ultrasound have been done within 6 months prior to randomization and radiographic studies, if indicated, are negative for metastasis~* Patient is a suitable candidate for radical prostatectomy or radiotherapy~PATIENT CHARACTERISTICS:~* ECOG performance status 0, 1, or 2~* Patient has a minimum life expectancy of \> 10 years~* In centers participating in the quality of life component of the study, the patient is able (i.e., sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French~* No history of other malignancies, except adequately treated non-melanoma skin cancer, adequately treated superficial bladder cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years from study randomization~PRIOR CONCURRENT THERAPY:~* No previous treatment for prostate cancer, including surgery (excluding biopsy and TURP), radiotherapy, or androgen deprivation therapy for greater than 3 months~* No planned androgen therapy except in the context of radical therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Surveillance (Type: NO_INTERVENTION): Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
- Radical Intervention (Type: ACTIVE_COMPARATOR): Radical prostatectomy or radiotherapy based on patient and physician preference

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Berries on Lung Cancer Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (lung cancer survivors):~* men treated for lung cancer, women treated for lung cancer and with no child-bearing potential (hysterectomy, tubal ligation, post-menopausal women)~Exclusion Criteria (lung cancer survivors):~* women who are on hormone replacement therapy~* women who are pregnant, or planning for pregnancy~* history of lung transplant~* prison inmate~* inability to take oral medication or food~* known or suspected allergy to berries or berry products~* HIV patients~Inclusion Criteria (volunteers):~* adult men, adult women with no child bearing potential (hysterectomy, tubal ligation, post-menopausal women)~Exclusion Criteria (volunteers):~* women who are on hormone replacement therapy~* women who are pregnant, or planning for pregnancy~* history of lung transplant~* prison inmate~* inability to take oral medication or food~* known or suspected allergy to berries or berry products~* HIV patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine in Patients With Mild and Severe Coronavirus Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients over 18 years of age~2. Diagnosed with COVID-19 with mild or severe disease~3. Who must receive in-hospital care at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran~4. Who are able to take pills PO~Exclusion Criteria:~* 1. Concomitant participation in another clinical trial. 2. Hypersensitivity to colchicine 3. Pregnancy and lactation 4. Over 70 years 5. Kidney failure with creatinine clearance \<30 mL / min. 6. Known liver failure 7. Concomitant medication that has interactions with colchicine and that due to its indication cannot be suspended or substituted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Colchicine (Type: ACTIVE_COMPARATOR): Colchicine PO
- Placebo (Type: PLACEBO_COMPARATOR): Placebo PO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Manual and Expressed Placental Removal at Cesarean Delivery and Its Effects on Various Cardiac Indices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant~* scheduled for cesarean delivery~* able to give informed consent~Exclusion Criteria:~* taking medications that may affect hemodynamics~* unable to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- manual (Type: ACTIVE_COMPARATOR): Manual removal of placenta
- expressed (Type: ACTIVE_COMPARATOR): expressed placental removal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of acute myeloid leukemia (AML) according to the World Health Organization (WHO) classification~* Diagnosis of AML which has relapsed or is refractory to standard of care and no curative therapy exists~* Karnofsky or Lansky score of at least 50~* Must be recovered from acute toxicity of any prior treatment~* Must have adequate organ function according to protocol-defined criteria~* Agrees to protocol-defined use of effective contraception~* Female participants of childbearing potential must have a negative serum or urine pregnancy test at Day 1 of Cycle 1~Exclusion Criteria:~* Prior treatment with decitabine or azacitidine~* Acute promyelocytic leukemia (M3 subtype in the French-American-British \[FAB\] classification system)~* CNS3 disease~* acute myeloid leukemia (AML) associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes~* White blood cell count greater than 40x10\^9 cells/liter(L)~* Known allergies, hypersensitivity, or intolerance to decitabine or cytarabine or their excipients~* Contraindications to the use of cytarabine per local prescribing information or prior adverse reactions to cytarabine which would prevent further use~* Currently enrolled in the treatment phase of an interventional investigational study~* Female who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study drug (however, the period after which it becomes safe to become pregnant after the last dose of treatment is not known)~* Male who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug~* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments~* Any social or medical condition that in the investigator's opinion renders the participant unfit for study participation~* History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease~* History of human immunodeficiency virus (HIV) antibody positive

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Decitabine and cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Frontal Bone Window in ICUF (FBW-ICU)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Membership in a health insurance scheme~* Patients with an acute cerebral pathology~* Hospitalized patients in a supportive care unit of Montpellier University Hospital~* Be able to benefit from transcranial doppler within 3 days of admission~Exclusion Criteria:~* Clinical suspicion of encephalic death~* Known allergy to ultrasound gel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcranial Doppler examination (Type: EXPERIMENTAL): Transcranial Doppler examination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Avelumab in Pediatric Cancer Participants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 0 to less than 18 years of age at the time of first treatment dose with histologically or cytologically confirmed solid malignant tumors (including CNS tumors) or lymphoma for which no standard therapy is available~* Confirmed progression on or refractory to standard therapy or no standard therapy available.~* Availability of archival formalin-fixed, paraffin-embedded block containing tumor tissue, or slides, or a fresh/recent tumor biopsy prior to avelumab treatment for subjects in Phase 2~* Adequate bone marrow, kidney, and liver function~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Prior therapy with any antibody or drug targeting T-cell coregulatory proteins~* Concurrent anticancer treatment or immunosuppressive agents~* Prior organ transplantation~* Significant acute or chronic infections~* Other significant diseases or conditions that might impair the subject's tolerance of trial treatment~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Avelumab: 10 miligram per kilogram (mg/kg) (Type: EXPERIMENTAL): None
- Avelumab 20mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Interest of Contact Precautions for Preventing Micro-organisms Acquisition in Patients Hospitalized in Infectious Disease Unit of University-affiliated Hospital in Rennes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient hospitalized in Infectious Diseases Unit during the study period in one of the selected part of the unit participating to the study~* Patient informed about the study protocol and approved to participate.~Exclusion Criteria:~* Patient requiring isolation prescription type air or droplet~* Patient hospitalized in the central sector of the building (including 4 bedrooms in depression negative service)~* Patient colonized with bacteria producing carbapenemase, multi-resistant Acinetobacter baumanii or Vancomycin-Resistant Enterococcus.~* Patients under legal protection (juridical protection, legal guardianship) or persons on juridical detention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard precautions (Type: None): One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design).
- contact precautions (Type: None): One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues